MedTrace Logo

Effects of Prolonged DAPT After Lower Extremity Percutaneous Transluminal Angioplasty (PTA) in Patients With LE-PAD

NCT02798913 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2019-02-15

No results posted yet for this study

Summary

The objective of the present study was to evaluate the prognostic impact of prolonged dual antiplatelet therapy (DAPT) with acetylsalicylic acid plus clopidogrel on the incidence of major adverse cardiovascular events and major adverse limb events after percutaneous lower extremity revascularization in patients with lower extremity peripheral arterial disease (LE-PAD).

Conditions

Interventions

DRUG

Short DAPT

acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 3 months

DRUG

Long DAPT

acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 12 months

Sponsors & Collaborators

  • Federico II University

    lead OTHER

Principal Investigators

  • Bruno Trimarco · Federico II University

  • Giovanni Esposito, MD, PhD · Federico II University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2020-06-30
Completion
2020-07-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02798913 on ClinicalTrials.gov